ATE246184T1 - Chinoline und deren therapeutische verwendung - Google Patents

Chinoline und deren therapeutische verwendung

Info

Publication number
ATE246184T1
ATE246184T1 AT97911344T AT97911344T ATE246184T1 AT E246184 T1 ATE246184 T1 AT E246184T1 AT 97911344 T AT97911344 T AT 97911344T AT 97911344 T AT97911344 T AT 97911344T AT E246184 T1 ATE246184 T1 AT E246184T1
Authority
AT
Austria
Prior art keywords
quinolines
therapeutic use
pde
tnf
compounds
Prior art date
Application number
AT97911344T
Other languages
English (en)
Inventor
Hazel Joan Dyke
John Gary Montana
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623163.4A external-priority patent/GB9623163D0/en
Priority claimed from GBGB9714298.8A external-priority patent/GB9714298D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE246184T1 publication Critical patent/ATE246184T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97911344T 1996-11-06 1997-11-06 Chinoline und deren therapeutische verwendung ATE246184T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9623163.4A GB9623163D0 (en) 1996-11-06 1996-11-06 Novel compounds
GBGB9714298.8A GB9714298D0 (en) 1997-07-07 1997-07-07 Quinolines and their therapeutic use
PCT/GB1997/003047 WO1998020007A1 (en) 1996-11-06 1997-11-06 Quinolines and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE246184T1 true ATE246184T1 (de) 2003-08-15

Family

ID=26310351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97911344T ATE246184T1 (de) 1996-11-06 1997-11-06 Chinoline und deren therapeutische verwendung

Country Status (7)

Country Link
EP (1) EP0946541B1 (de)
JP (1) JP2001503756A (de)
AT (1) ATE246184T1 (de)
AU (1) AU711587B2 (de)
CA (1) CA2268126A1 (de)
DE (1) DE69723863T2 (de)
WO (1) WO1998020007A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) * 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
HK1045306A1 (zh) * 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
GB0007934D0 (en) * 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
DK1463493T3 (da) 2001-12-14 2008-02-04 Serono Lab Fremgangsmåder til at inducere æglösning ved anvendelse af en ikke polypeptid-cAMP-niveaumodulator
PE20050676A1 (es) 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
AU2005247906B2 (en) * 2004-05-18 2011-08-25 Merck Sharp & Dohme Corp. Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
KR20180030913A (ko) 2015-07-30 2018-03-26 브리스톨-마이어스 스큅 컴퍼니 아릴 치환된 비시클릭 헤테로아릴 화합물
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2018013774A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307570A (pt) * 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv

Also Published As

Publication number Publication date
AU4875897A (en) 1998-05-29
DE69723863D1 (de) 2003-09-04
AU711587B2 (en) 1999-10-14
WO1998020007A1 (en) 1998-05-14
JP2001503756A (ja) 2001-03-21
DE69723863T2 (de) 2004-04-15
EP0946541B1 (de) 2003-07-30
CA2268126A1 (en) 1998-05-14
EP0946541A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
YU21401A (sh) Tetrahidropiridoetri
ATE258437T1 (de) Chinolone und deren therapeutische verwendung
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
MX9700557A (es) Dihidrobenzofuranos.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
FI935585A0 (fi) Pyrrolopyrimidiner
DK0882021T3 (da) Nye phenanthridiner
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
DE69108048D1 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
DE69723447D1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
DE69922216D1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
BR9910864A (pt) Compostos anti-inflamatórios para inibição de aderência celular
PT815087E (pt) Derivados de fenilo trissubstituidos
DE69732966D1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
IT1285770B1 (it) Composti corticoidei
BR9809185A (pt) Diidropiranos fundidos
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
NZ513096A (en) Compositions for treating inflammatory response

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties